Abstract
Serous papillary carcinomas (SPCs) share a similar morphology regardless of whether they originate from the ovary or the uterus. Identification of the site of origin of the tumor can be a challenging and a diagnostic dilemma, particularly, in the setting of a pelvic mass or peritoneal carcinomatosis. Recognition of the site of origin influences the staging, management, and prognosis of these malignancies. The purpose of this study is to identify a panel of markers to distinguish the ovarian serous papillary carcinomas (OSPC) from the uterine serous papillary carcinomas (USPC). Formalin-fixed, paraffin-embedded archival tissue from 46 cases of SPCs (33 uterine and 13 ovarian) were stained using antibodies for estrogen receptor (ER), WT1, insulin-like growth factor-II mRNA-binding protein 3 (IMP3), p53, and p16. The OSPC expressed ER (92%), WT1 (100%), IMP3 (92%), p53 (92%), and p16 (92%). The USPCs expressed ER (30%), WT1 (64%), IMP3 (85%), p53 (64%), and p16 (76%). Only ER expression was significantly higher in OSPC compared with USPCs (P<0.001). The combined ERWT1 phenotype was present in 92% of the OSPC, whereas only 18% of the USPCs had the same phenotype (P<0.001). Furthermore, 71% of the OSPCs expressed ER, p53, WT1, IMP3, and p16 immunophenotype, whereas in USPCs, the tumor cells showed immunophenotypic diversity, with only 6% of the USPCs expressing reactivity to all the 5 markers (P<0.001). This study suggests that ER alone or in combination with a limited panel of markers may be used to identify the site of origin of SPCs.
| Original language | English |
|---|---|
| Pages (from-to) | 476-481 |
| Number of pages | 6 |
| Journal | International Journal of Gynecological Pathology |
| Volume | 32 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2013 |
| Externally published | Yes |
Fingerprint
Keywords
- ER
- IMP3
- Ovarian
- p16
- p53
- Serous papillary carcinoma
- Uterine
- WT1
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Obstetrics and Gynecology
Cite this
An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas. / Zhang, Yaxia; Garcia-Buitrago, Monica; Sengul, Tulay; Schuman, Samer; Ganjei-Azar, Parvin.
In: International Journal of Gynecological Pathology, Vol. 32, No. 5, 01.09.2013, p. 476-481.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas
AU - Zhang, Yaxia
AU - Garcia-Buitrago, Monica
AU - Sengul, Tulay
AU - Schuman, Samer
AU - Ganjei-Azar, Parvin
PY - 2013/9/1
Y1 - 2013/9/1
N2 - Serous papillary carcinomas (SPCs) share a similar morphology regardless of whether they originate from the ovary or the uterus. Identification of the site of origin of the tumor can be a challenging and a diagnostic dilemma, particularly, in the setting of a pelvic mass or peritoneal carcinomatosis. Recognition of the site of origin influences the staging, management, and prognosis of these malignancies. The purpose of this study is to identify a panel of markers to distinguish the ovarian serous papillary carcinomas (OSPC) from the uterine serous papillary carcinomas (USPC). Formalin-fixed, paraffin-embedded archival tissue from 46 cases of SPCs (33 uterine and 13 ovarian) were stained using antibodies for estrogen receptor (ER), WT1, insulin-like growth factor-II mRNA-binding protein 3 (IMP3), p53, and p16. The OSPC expressed ER (92%), WT1 (100%), IMP3 (92%), p53 (92%), and p16 (92%). The USPCs expressed ER (30%), WT1 (64%), IMP3 (85%), p53 (64%), and p16 (76%). Only ER expression was significantly higher in OSPC compared with USPCs (P<0.001). The combined ERWT1 phenotype was present in 92% of the OSPC, whereas only 18% of the USPCs had the same phenotype (P<0.001). Furthermore, 71% of the OSPCs expressed ER, p53, WT1, IMP3, and p16 immunophenotype, whereas in USPCs, the tumor cells showed immunophenotypic diversity, with only 6% of the USPCs expressing reactivity to all the 5 markers (P<0.001). This study suggests that ER alone or in combination with a limited panel of markers may be used to identify the site of origin of SPCs.
AB - Serous papillary carcinomas (SPCs) share a similar morphology regardless of whether they originate from the ovary or the uterus. Identification of the site of origin of the tumor can be a challenging and a diagnostic dilemma, particularly, in the setting of a pelvic mass or peritoneal carcinomatosis. Recognition of the site of origin influences the staging, management, and prognosis of these malignancies. The purpose of this study is to identify a panel of markers to distinguish the ovarian serous papillary carcinomas (OSPC) from the uterine serous papillary carcinomas (USPC). Formalin-fixed, paraffin-embedded archival tissue from 46 cases of SPCs (33 uterine and 13 ovarian) were stained using antibodies for estrogen receptor (ER), WT1, insulin-like growth factor-II mRNA-binding protein 3 (IMP3), p53, and p16. The OSPC expressed ER (92%), WT1 (100%), IMP3 (92%), p53 (92%), and p16 (92%). The USPCs expressed ER (30%), WT1 (64%), IMP3 (85%), p53 (64%), and p16 (76%). Only ER expression was significantly higher in OSPC compared with USPCs (P<0.001). The combined ERWT1 phenotype was present in 92% of the OSPC, whereas only 18% of the USPCs had the same phenotype (P<0.001). Furthermore, 71% of the OSPCs expressed ER, p53, WT1, IMP3, and p16 immunophenotype, whereas in USPCs, the tumor cells showed immunophenotypic diversity, with only 6% of the USPCs expressing reactivity to all the 5 markers (P<0.001). This study suggests that ER alone or in combination with a limited panel of markers may be used to identify the site of origin of SPCs.
KW - ER
KW - IMP3
KW - Ovarian
KW - p16
KW - p53
KW - Serous papillary carcinoma
KW - Uterine
KW - WT1
UR - http://www.scopus.com/inward/record.url?scp=84883454172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883454172&partnerID=8YFLogxK
U2 - 10.1097/PGP.0b013e31826ddc4e
DO - 10.1097/PGP.0b013e31826ddc4e
M3 - Article
C2 - 23896709
AN - SCOPUS:84883454172
VL - 32
SP - 476
EP - 481
JO - International Journal of Gynecological Pathology
JF - International Journal of Gynecological Pathology
SN - 0277-1691
IS - 5
ER -